These findings, in both FXS mice and humans, are consistent with the idea that the loss of FMRP results in the dysregulation of mechanisms of translational initiation control rather than transcriptional regulation and provide the direct evidence that mTOR dysregulation may be useful for designing targeted treatments in FXS [136]. The gene discussed is MTOR; the disease is fragile X syndrome.